The report will be delivered in 2-3 business days.

Biosimilar Growth Hormones Global Market Report 202 - By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Speciality Clinics), COVID-19 Growth And Change

Starting Price : $5000.00 | Pages : 175 | Published : March 2021 | SKU CODE : 7704 | Format :


The biosimilar growth hormone market consists of sales of Somatropin or human growth hormone (HGH) and related services by entities (organizations, sole traders and partnerships) that manufacture growth hormones. Biosimilar growth hormones are used to stimulate growth, cell reproduction and cell regeneration in humans and other animals.

The biosimilar growth hormone market covered in this report is segmented by route of administration into intravenous, subcutaneous, intramuscular, oral. The biosimilar growth hormone market is also segmented by application into growth hormone deficiency, turner syndrome, idiopathic short stature, prader willi syndrome, others; by distribution channel into hospital and retail pharmacy, online pharmacy/epharmacy, specialty clinics.

The global biosimilar growth hormones market is expected to grow from $0.52 billion in 2020 to $0.56 billion in 2021 at a compound annual growth rate (CAGR) of 7.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar growth hormone market is expected to reach $0.78 billion in 2025 at a CAGR of 9%.

The growing number of children suffering from growth hormone deficiency is driving the growth of the global biosimilar growth hormone market. Growth hormone deficiency is caused by damage to the pituitary gland or hypothalamus, which may be the result of an abnormal formation that occurred before the child was born (congenital) or something that occurred during or after birth (acquired). Growth hormone deficiency has been identified in about 1 in every 3,800 babies. Additionally, some children acquire it later in their life as a result of a brain tumor, brain operation, radiation therapy, injury or infection. Thus, an increase in the number of children suffering from growth deficiency drives the growth of the market.

The growing awareness about the side effects caused by the continuous usage of the biosimilar growth hormones is expected to restrict the growth of the market. Possible side effects of HGH use include nerve, muscle, or joint pain, swelling due to fluid in the body's tissues (edema), carpal tunnel syndrome, numbness and tingling of the skin, and high cholesterol levels. Continuous dosage of HGH can also increase the risk of diabetes and contribute to the growth of cancerous tumors, thus restraining the growth of the market.

Recombinant DNA technology (rDNA technology) is increasingly being implemented in the biosimilar growth hormone industry. The development of biosimilar growth hormone by using recombinant DNA technology (rDNA technology) is an emerging trend. For instance, in 2018, Genevatropin was produced utilizing Recombinant DNA Secretion Technology. Genevatropin® (Genevatropin [rDNA origin] injectable delivery) is a pharmaceutical solution that supplements the natural human growth hormone for people who may be deficient in this hormone.

In October 2018, Strongbridge Biopharma Plc entered into an agreement with Novo Nordisk to acquire the U.S. and Canadian rights of MACRILEN™ (macimorelin) for a deal amount of $145 million. The deal is expected to boost Novo Nordisk’s biopharma business. Macrilen is an oral growth hormone secretagogue receptor agonist that is indicated for the diagnosis of adult growth hormone deficiency (AGHD). Strongbridge Biopharma is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with unmet needs.

Major players in the biosimilar growth hormone market are Biopartners And LG Chem, Amega Biotech, Eli Lilly and Company, Genetech Inc., Novartis AG, Zhongshan Hygene Biopharm Co. Ltd., Merck, Sanofi S.A., Biosidus, Ferring Pharmaceuticals.

The regions covered in the biosimilar growth hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biosimilar growth hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global biosimilar growth hormones market is segmented -

1) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular, Oral

2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Others

3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Speciality Clinics

    Table Of Contents

    1. Executive Summary

    2. Biosimilar Growth Hormones Market Characteristics

    3. Biosimilar Growth Hormones Market Trends And Strategies

    4. Impact Of COVID-19 On Biosimilar Growth Hormones

    5. Biosimilar Growth Hormones Market Size And Growth

    5.1. Global Biosimilar Growth Hormones Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Biosimilar Growth Hormones Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Biosimilar Growth Hormones Market Segmentation

    6.1. Global Biosimilar Growth Hormones Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Intravenous 

    Subcutaneous 

    Intramuscular 

    Oral 

    6.2. Global Biosimilar Growth Hormones Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Growth Hormone Deficiency

    Turner Syndrome

    Idiopathic Short Stature

    Prader Willi Syndrome

    Others

List Of Tables

    Table 1: 6.3. Global Biosimilar Growth Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 2: Hospital And Retail Pharmacy
  • Table 3: Online Pharmacy/ePharmacy
  • Table 4: Speciality Clinics
  • Table 5:

List Of Figures

    Figure 1: 6.3. Global Biosimilar Growth Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 2: Hospital And Retail Pharmacy
  • Figure 3: Online Pharmacy/ePharmacy
  • Figure 4: Speciality Clinics
  • Figure 5:
Global Psoriasis Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Psoriatic Arthritis Treatment Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Regenerative Medicine For Cartilage Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Radiopharmaceuticals Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Remdesivir Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Research Antibodies and Reagents Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Rituximab Biosimilars Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Respiratory Diseases Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Biosimilar Monoclonal Antibodies Global Market Report 2021 - By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), COVID-19 Growth And Change
View Report
Biosimilar Therapeutic Peptides Global Market Report 2021 - By Route Of Administration (Parenteral Route, Transdermal Route), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders), By Type (Innovative, Generic), COVID-19 Growth And Change
View Report
Rituximab Biosimilars Global Market Report 2021 - By Application (Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels), By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), COVID-19 Growth And Change
View Report
Biosimilar Hormones Global Market Report 2021 - By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics), COVID-19 Growth And Change
View Report
Biosimilar Lymphocyte Modulator Global Market Report 2021 - By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis), COVID-19 Growth And Change
View Report
Biosimilars Global Market Report 2021 - By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), COVID-19 Growth And Change
View Report
Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030
View Report
Pegfilgrastim Biosimilars Market - By Application (Chemotherapy Induced Neutropenia, Transplantation, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies), And By Region, Opportunities And Strategies – Global Pegfilgrastim Biosimilars Market Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)